Taysha Gene Therapies Soars 53% on Baird's Upgraded $12 Price Target

Shares of Taysha Gene Therapies (NASDAQ: TSHA) skyrocketed over 53% in recent trading, fueled by a significant vote of confidence from Wall Street. The surge occurred after analysts at Baird substantially increased their price target on the stock to $12.00 from a previous $7.00, while reiterating an 'Outperform' rating.

The massive influx of buying activity pushed trading volume to more than 27 times its daily average, signaling strong investor conviction behind the upgrade. The primary catalyst for Baird's optimistic revision is the , the company's lead gene therapy candidate for the treatment of Rett Syndrome, a rare and severe neurodevelopmental disorder.

Taysha recently announced it has achieved regulatory alignment with the U.S. Food and Drug Administration (FDA) for the therapy's pivotal study. The FDA has agreed to a streamlined 15-patient study size with a 6-month interim analysis timeline, a development which Baird analysts believe makes the trial "highly likely to be successful."

Further bolstering the case for TSHA-102, the FDA also granted the candidate . This status is intended to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. The designation was supported by clinical data from the REVEAL Phase 1/2 trials, which demonstrated a promising response rate among treated patients.

The sharp upward move in Taysha's stock price has pushed it into technically overbought territory, with a Relative Strength Index (RSI) of 80.52. While this may suggest a potential for a short-term pullback, the fundamental story has clearly resonated with investors, who are now looking ahead to the pivotal study's enrollment, which is expected to begin in the fourth quarter of 2025.